Japan’s Astellas to pay $3B for US Audentes

Japanese pharmaceutical company Astellas Pharma agreed to acquire US peer Audentes Therapeutics for about $3 billion in cash. Audentes shareholders will receive $60 for each share they own. The transaction price represents a 110% premium to Audentes closing price on Monday. The deal was approved by both boards and recommended shareholders to do the same. […]